Predicted rates of secondary malignancies from proton versus photon radiation therapy for stage i seminoma

International Journal of Radiation Oncology Biology Physics

Volumn 82, Issue 1, 2012, Pages 242-249

  Simone II, Charles B ^a,b   Kramer, Kevin ^c   O'Meara, William P ^d   Bekelman, Justin E ^a   Belard, Arnaud ^c   McDonough, James ^a   O'Connell, John ^d  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Dosimetry; Para aortic; Proton therapy; Secondary malignancies; Seminoma

Indexed keywords

ABSOLUTE REDUCTION; ACUTE TOXICITY; ADJUVANT TREATMENT; CALCULATED VALUES; CARBOPLATIN; COMPUTED TOMOGRAPHY; CONFIDENCE INTERVAL; CRITICAL STRUCTURES; IN-FIELD; INCIDENCE RATE; LARGE BOWEL; LIFE EXPECTANCIES; MEAN DOSE; NORMAL TISSUE; ORGAN EQUIVALENT DOSE; PARA-AORTIC; PHOTON RADIATION; PHOTON RADIOTHERAPY; PROTON RADIATION THERAPY; PROTON RADIATIONS; PROTON RADIOTHERAPY; PROTON THERAPY; RADIATION TREATMENTS; RADIATION-INDUCED CANCER; RADIATION-INDUCED TOXICITY; SECONDARY CANCER RISK; SECONDARY MALIGNANCIES; SEMINOMA; SINGLE-DOSE; TARGET VOLUMES; TREATMENT MODALITY;

COMPUTERIZED TOMOGRAPHY; DISEASES; DOSIMETRY; PHOTONS; PROTON BEAMS; PROTONS; RADIATION; TISSUE; TOMOGRAPHY; TOXICITY;

RADIOTHERAPY;

ADULT; ARTICLE; BLADDER; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CANCER SURVIVOR; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; HUMAN; INTERMETHOD COMPARISON; KIDNEY; LARGE INTESTINE; LIFE EXPECTANCY; MALE; PANCREAS; PHOTON THERAPY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTON THERAPY; RADIATION DOSE; RADIATION INDUCED NEOPLASM; SECOND CANCER; SEMINOMA; STOMACH; TESTIS CANCER;

ADULT; HUMANS; INTESTINE, LARGE; LIFE EXPECTANCY; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; ORGANS AT RISK; PANCREAS; PHOTONS; PROTONS; RADIOTHERAPY DOSAGE; SEMINOMA; STOMACH; TESTICULAR NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; URINARY BLADDER; YOUNG ADULT;

EID: 83955165974     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.11.021     Document Type: Article

References (33)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2009 CA Cancer J Clin 59 4 2009 225 249
2. M.H. Sokoloff, G.F. Joyce, and M. Wise Testis cancer J Urol 177 6 2007 2030 2041
3. W.G. Jones, S.D. Fossa, and G.M. Mead Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328) J Clin Oncol 23 6 2005 1200 1208
4. S.D. Foss, A. Horwich, and J.M. Russell for the Medical Research Council Testicular Tumor Working Group. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial J Clin Oncol 17 4 1999 1146
5. S. Bieri, M. Rouzaud, and R. Miralbell Seminoma of the testis: is scrotal shielding necessary when radiotherapy is limited to the para-aortic nodes? Radiother Oncol 50 3 1999 349 353
6. G.K. Zagars, M.T. Ballo, and A.K. Lee Mortality after cure of testicular seminoma J Clin Oncol 22 4 2004 640 647
7. G.E. Hanks, T. Peters, and J. Owen Seminoma of the testis: long-term beneficial and deleterious results of radiation Int J Radiat Oncol Biol Phys 24 5 1992 913 919
8. R.T. Oliver, G.M. Mead, and P.J. Fogarty Radiotherapy versus carboplatin for stage I seminoma: updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214) J Clin Oncol 26 Suppl 15 2008 A-1
9. R.T. Oliver, M.D. Mason, and G.M. Mead Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial Lancet 366 9482 2005 293 300
10. L.B. Travis, S.D. Foss, and S.J. Schonfeld Second cancers among 40,576 testicular cancer patients: focus on long-term survivors J Natl Cancer Inst 97 18 2005 1354 1365
11. D. Robinson, H. Moller, and A. Horwich Mortality and incidence of second cancers following treatment for testicular cancer Br J Cancer 96 3 2007 529 533
12. C. Schairer, M. Hisada, and B.E. Chen Comparative mortality for 621 second cancers in 29356 testicular cancer survivors and 12420 matched first cancers J Natl Cancer Inst 99 16 2007 1248 1256
13. C.L. Kennedy, W.F. Hendry, and M.J. Peckham The significance of scrotal interference in stage I testicular cancer managed by orchiectomy and surveillance Br J Urol 58 6 1986 705 708
14. H. Suit, S. Goldberg, and A. Niemierko Proton beams to replace photon beams in radical dose treatments Acta Oncol 42 8 2003 800 808
15. H. Paganetti, A. Niemierko, and M. Ancukiewicz Relative biological effectiveness (RBE) values for proton beam therapy Int J Radiat Oncol Biol Phys 53 2 2002 407 421
16. U. Schneider, and B. Kaser-Hotz A simple dose-response relationship for modeling secondary cancer incidence after radiotherapy Z Med Phys 15 1 2005 31 37
17. U. Schneider, D. Zwahlen, and D. Ross Estimation of radiation-induced cancer from three-dimensional dose distributions: Concept of organ equivalent dose Int J Radiat Oncol Biol Phys 61 5 2005 1510 1515
18. U. Schneider, A. Lomax, and J. Besserer The impact of dose escalation on secondary cancer risk after radiotherapy of prostate cancer Int J Radiat Oncol Biol Phys 68 3 2007 892 897
19. P. Warde, L. Specht, and A. Horwich Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis J Clin Oncol 20 22 2002 4448 4452
20. S. Krege, J. Beyer, and R. Souchon European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I Eur Urol 53 3 2008 478 496
21. National Comprehensive Cancer Network. The NCCN clinical practice guidelines in oncology: testicular cancer, version 1.2010. August 28, 2009. National Comprehensive Cancer Network, Inc. Available at: NCCN.org. Accessed February 22, 2010.
22. J. Aparicio, X. García del Muro, and P. Maroto Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma Ann Oncol 14 6 2003 867 872
23. T.V. Tarin, G. Sonn, and R. Shinghal Estimating the risk of cancer associated with imaging related radiation during surveillance for stage I testicular cancer using computerized tomography J Urol 181 2 2009 627 632
24. L.B. Travis, M. Andersson, and M. Gospodarowicz Treatment-associated leukemia following testicular cancer J Natl Cancer Inst 92 14 2000 1165 1171
25. R. Howard, E. Gilbert, and C.F. Lynch Risk of leukemia among survivors of testicular cancer: a population-based study of 42,722 patients Ann Epidemiol 18 5 2008 416 421
26. L.B. Travis, R.E. Curtis, and B.F. Hankey Second malignancies after testicular cancer J Clin Oncol 13 2 1995 533 534
27. D.R. Zwahlen, J.M. Martin, and J.L. Millar Effect of radiotherapy volume and dose on secondary cancer risk in stage I testicular seminoma Int J Radiat Oncol Biol Phys 70 3 2008 853 858
28. C. Zacharatou Jarlskog, and H. Paganetti Risk of developing second cancer from neutron dose in proton therapy as function of field characteristics, organ, and patient age Int J Radiat Oncol Biol Phys 72 1 2008 228 235
29. B.S. Athar, B. Bednarz, and J. Seco Comparison of out-of-field photon doses in 6 MV IMRT and neutron doses in proton therapy for adult and pediatric patients Phys Med Biol 55 10 2010 2879 2891
30. U. Schneider, A. Lomax, and P. Pemler The impact of IMRT and proton radiotherapy on secondary cancer incidence Strahlenther Onkol 182 11 2006 647 652
31. J.P. Donohue, J.M. Zachary, and B.R. Maynard Distribution of nodal metastases in nonseminomatous testis cancer J Urol 128 2 1982 315 320
32. J.H. Gagnon, B.M. Mount, and H. Khonsari Lymphography in germinal tumours of the testis Br J Urol 44 2 1972 136 142
33. M.L. Brown, B.J. Gersh, and D.R. Holmes From randomized trials to registry studies: translating data into clinical information Nat Clin Pract Cardiovasc Med 5 10 2008 613 620